Chronic intracerebroventricular administration of beta-endorphin augments natural killer cell cytotoxicity in rats.
We have studied the effect of chronic intracerebroventricular (i.c.v.) infusion of different opioid peptides on natural killer (NK) cell mediated cytotoxicity in vivo in the spontaneously hypertensive rat (SHR). The in vivo NK cell activity was measured as the clearance of 51Cr-labelled YAC-l lymphoma cells from the lung tissues. Further, the phenotype of lymphocytes in spleen and peripheral blood was analysed by flow cytometry (FACS). All opioid drugs were administered i.c.v. for 6 days with osmotic minipumps releasing 1.0 microliter/h. beta-Endorphin (10 or 20 micrograms/rat per day) significantly increased NK cell cytotoxicity in vivo. The opioid receptor antagonist naloxone (10 mg/kg, i.p.) given immediately before the injection of YAC-lymphoma cells, completely abolished the effects of i.c.v. administered beta-endorphin. Corresponding doses of beta-endorphin administered subcutaneously (s.c.) with minipumps for 6 days did not significantly affect NK cell cytotoxicity. Neither Leu- or Met-enkephalin (20 micrograms/rat per day) nor dynorphin (20 micrograms/rat per day) administered i.c.v. had any significant effects on NK cell activity. In beta-endorphin treated SHR, the percentage of cells with NK cell phenotype (OX52+/CD5-) in peripheral blood was not significantly different from that of controls, while the percentage of cells with T cell phenotype (CD5+/OX52-) was significantly decreased. The percentage of splenic NK cells (OX52+/CD5-) and T cells (CD5+/OX52-) was also unchanged by beta-endorphin treatment i.c.v. These results suggest that of the opioid peptides administered i.c.v., only beta-endorphin augments in vivo NK cell mediated cytotoxicity. We thus conclude that these effects most probably are centrally and opioid receptor mediated effects, since beta-endorphin in the same dose administered peripherally does not influence in vivo NK cell cytotoxicity.
Jonsdottir
I H
IH
Department of Physiology, Göteborg University, Sweden.
Johansson
C
C
Asea
A
A
Hellstrand
K
K
Thorén
P
P
Hoffmann
P
P
D000279:Administration, Cutaneous; D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004399:Dynorphins / Q000008:administration & dosage; D004745:Enkephalins / Q000008:administration & dosage; D007276:Injections, Intraventricular; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008223:Lymphoma / Q000276:immunology / Q000473:pathology; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D014407:Tumor Cells, Cultured; D001615:beta-Endorphin / Q000008:administration & dosage*
D004745:Enkephalins; D001615:beta-Endorphin; D004399:Dynorphins